11 unknown, 2 completed, 2 withdrawn. 12 Phase 2, 3 Phase 1, 3 Phase 3.
By phase and status
Follow SCTV01C vaccine: new trials by email Literature Review of SCTV01C vaccine trials Research Report on SCTV01C vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
SCTV01E-2, SCTV01E - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 600 | 2023-08-10 | 2023-07-06 |
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People
CoronaVac, SCTV01E - COVID-19 SARS-CoV-2 Infection | Phase 3 | Unknown | Sinocelltech Ltd. | 6000 | 2023-01-25 | 2023-01-13 |
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
SCTV01E, Placebo (normal saline) - COVID-19 Pandemic | Phase 2 | Completed | Sinocelltech Ltd. | 518 | 2023-01-05 | 2024-02-08 |
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
SCTV01E, Placebo - COVID-19, SARS-CoV-2 Infection | Phase 3 | Unknown | Sinocelltech Ltd. | 10000 | 2022-12-26 | 2024-04-15 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
SCTV01E, mRNA-1273 - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 300 | 2022-07-01 | 2022-04-26 |
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
SCTV01E, Comirnaty - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Unknown | Sinocelltech Ltd. | 400 | 2022-07-01 | 2022-04-14 |
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 3 | Unknown | Sinocelltech Ltd. | 1800 | 2022-05-30 | 2023-04-10 |
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
SCTV01C, Comirnaty - COVID-19, SARS-CoV2 Infection | Phase 2 | Withdrawn | Sinocelltech Ltd. | | 2022-04-25 | 2024-02-09 |
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 400 | 2022-04-01 | 2022-04-11 |
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
SCTV01C, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna - COVID-19, SARS-CoV-2 Infection | Phase 2 | Withdrawn | Sinocelltech Ltd. | | 2022-04-01 | 2024-02-09 |
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
SCTV01E, Comirnaty - COVID-19, Sars-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 360 | 2022-03-20 | 2022-03-02 |
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
SCTV01C, Sinopharm inactivated COVID-19 vaccine, Comirnaty - COVID-19, SARS-CoV-2 Infection | Phase 2 | Unknown | Sinocelltech Ltd. | 600 | 2022-03-20 | 2022-03-02 |
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
SCTV01C, Placebo - COVID-19, SARS-CoV-2 Infection | Phase 1 / Phase 2 | Unknown | Sinocelltech Ltd. | 300 | 2021-12-22 | 2022-01-25 |
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
SCTV01C, Placebo - COVID-19, SARS-CoV-2 Infection | Phase 1 / Phase 2 | Unknown | Sinocelltech Ltd. | 300 | 2021-12-22 | 2022-01-25 |
The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults
SCTV01C, Adjuvant, Saline - COVID-19 | Phase 1 / Phase 2 | Completed | Sinocelltech Ltd. | 478 | 2021-12-01 | 2024-02-08 |
Conditions studied
COVID-19 (14)
Sponsors
Sinocelltech Ltd. (15)
Countries
China (3) · United Arab Emirates (3)
Top investigators
Yang Wang, Ph.D. (2) · Yimin Cui, M.D. (1) · Yu Sun (1) · Zhu Fengcai (1)
Results publications
PMID 36403700, PMID 36470077, PMID 36598621, PMID 37731938, PMID 39834144, PMID 41012186